Get started
Author

Giulia Apollonio

Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients
2019 · Federico Nichetti, Francesca Ligorio, et al. · Cancers · 66
PDF
The Pan-Immune-Inflammation Value in Patients with Metastatic Melanoma Receiving First-Line Therapy
2021 · Giovanni Fucà, Teresa Beninato, et al. · Targeted Oncology · 61
Androgen and Estrogen Receptor Imaging in Metastatic Breast Cancer Patients as a Surrogate for Tissue Biopsies
2017 · Clasina M. Venema, Lemonitsa H. Mammatas, et al. · Journal of Nuclear Medicine · 61
PDF
Sorafenib Versus Observation Following Radical Metastasectomy for Clear-cell Renal Cell Carcinoma: Results from the Phase 2 Randomized Open-label RESORT Study
2019 · Giuseppe Procopio, Giulia Apollonio, et al. · European Urology Oncology · 56
Recommendations and Technical Aspects of 16α-[18F]Fluoro-17β-Estradiol PET to Image the Estrogen Receptor In Vivo
2016 · Clasina M. Venema, Giulia Apollonio, et al. · Clinical Nuclear Medicine · 54
Collecting ducts carcinoma: An orphan disease. Literature overview and future perspectives
2019 · Filippo Pagani, Maurizio Colecchia, et al. · Cancer Treatment Reviews · 30
Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer With Uncommon Histology
2021 · Sara Manglaviti, Marta Brambilla, et al. · Clinical Lung Cancer · 17
Comparing BamHI-W and CE-marked assays to detect circulating Epstein-Barr Virus (EBV) DNA of nasopharyngeal cancer patients in a non-endemic area
2022 · Francesca Taverna, Salvatore Alfieri, et al. · Oral Oncology · 11
The role of metastasectomy in advanced renal cell carcinoma
2019 · Giulia Apollonio, Alessandra Raimondi, et al. · Expert Review of Anticancer Therapy · 11
Safety and activity of radium-223 in metastatic castration-resistant prostate cancer: the experience of Istituto Nazionale dei Tumori
2020 · Alessandra Raimondi, Pierangela Sepe, et al. · Tumori Journal · 8
High bone tumor burden to identify advanced non-small cell lung cancer patients with survival benefit upon bone targeted agents and immune checkpoint inhibitors
2023 · Sara Manglaviti, Marta Bini, et al. · Lung Cancer · 7
SARS-CoV-2 vaccine in patients with thymic epithelial tumours with and without active or pre-existing autoimmune disorders: Brief report of a TYME network safety analysis
2022 · Federica Giugliano, Paolo A. Zucali, et al. · European Journal of Cancer · 5
PDF
Prognostic role of neutrophil-to-lymphocyte ratio and EPSILoN score in advanced non-small-cell lung cancer patients treated with first-line chemo-immunotherapy
2022 · Emma Zattarin, Sara Manglaviti, et al. · Future Oncology · 4
Management of loco-regionally advanced squamous laryngeal cancer in elderly patients
2020 · Stefano Cavalieri, Ester Orlandi, et al. · European Archives of Oto-Rhino-Laryngology · 4
Baseline and early change of neutrophil to lymphocyte ratio (bNLR and ΔNLR) as prognostic factors in metastatic renal cell carcinoma (mRCC) patients treated with nivolumab: Preliminary results of the Meet-URO 15 (I-BIO-REC) study.
2020 · Sara Elena Rebuzzi, Sebastiano Buti, et al. · Journal of Clinical Oncology · 4
Hyperprogressive disease (HPD) in head and neck squamous cell carcinoma (HNSCC) patients treated with immune checkpoint inhibitors (ICI).
2019 · Salvatore Alfieri, Roberto Ferrara, et al. · Journal of Clinical Oncology · 3
Androgen receptor and estrogen receptor imaging in patients with metastatic breast cancer.
2016 · Clasina Marieke Venema, Lemonitsa H. Mammatas, et al. · Journal of Clinical Oncology · 3
Qualitative and quantitative analyses of F-18-FES and F-18-FDHT uptake in patients with metastatic breast cancer: an interobserver variability study
2017 · Mammatas, L. H., Venema, C. M., et al. · University of Groningen research database (University of Groningen / Centre for Information Technology) · 1
Prolonged disease control with trabectedin in metastatic EWSR1::PATZ1 sarcoma: a case report
2026 · A. Sargsyan, S. Brotea-Mosoiu, et al. · ESMO rare cancers.
1741P Ethically-sensitive clinical scenarios in adult patients with sarcomas: A real-world single-institution survey and a classification attempt
2024 · P.G. Casali, S. Provenzano, et al. · Annals of Oncology
PDF
15 First-line platinum-based chemotherapy combined with PD-1/PD-L1 inhibitors (ICI) prevents hyperprogression in non-small cell lung cancer (NSCLC) patients by reducing circulating immature neutrophils
2021 · Roberto Ferrara, Giuseppe Lo Russo, et al. · Journal for ImmunoTherapy of Cancer
PDF
P50.06 First-Line Therapy in NSCLC harbouring EGFR or HER2 Exon 20 Insertion Mutation. Hunting for the Best Candidate
2021 · A. Prelaj, A. Bottiglieri, et al. · Journal of Thoracic Oncology
PDF
P40.19 Efficacy and Toxicity of Third-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer
2021 · T. Beninato, S. Manglaviti, et al. · Journal of Thoracic Oncology
P40.08 Bone-Targeted Agents Improve Survival in High Bone Tumor Burden Advanced Non-Small-Cell-Lung Cancer Patients Treated With PD-(L)1 Inhibitors
2021 · S. Manglaviti, M. Bini, et al. · Journal of Thoracic Oncology
1311P The role of inflammatory biomarkers in advanced non-small cell lung cancer patients treated with chemo-immunotherapy
2021 · E. Zattarin, S. Manglaviti, et al. · Annals of Oncology
PDF
Works count: 32
Citation count: 406
H-index: 9
I10-index: 9
Year
Topic
Type